Konspiracje nie istnieja! Zapytaj Monike C. z Radia bZdet.

Liczba wypowiedzi w tym wątku: 1

1. Data: 2000-09-15 15:14:34

Temat: Konspiracje nie istnieja! Zapytaj Monike C. z Radia bZdet.
Od: Dziubdzius <k...@u...net> szukaj wiadomości tego autora

Monisia C. z Radia bZdet, tudiez jej intelektualna kolezanka,
Agniesia K. z organu pana Michnika Gazety Wyborczej, nie wierza, ze cos
takiego jak miedzynarodowe konspiracje istnieje.
Bebnia za to historyjki jak to pewnej kobiecie w Teksasie wyrosla broda.

Tutaj jest autentyczne info nt. zarzutu konspiracyjnego wymyslenia
zaburzenia ADHD przez czolowego ogloszeniodawce Gazety Wyborczej,
sponsora wyborczego Pieknego Mania, firme farmaceutyczna Novartis.
http"//www.novartis.pl

Pan Dick Scruggs, nb, to ten facio ktory na wlasny koszt wytoczyl
pierwszy pozew stanu Mississippi przeciwko Philip Morris et al o zwrot
kosztow leczenia raka pluc. I wygral. Jest on rowniez przedstawiony w
filmie The Insider/Informator (to ten adwokat z poludniowym akcentem,
ktory prowadzi wlasny samolot).
Wiecej o nim:
http://www.pbs.org/wgbh/pages/frontline/shows/settle
ment/deal/people/scr
uggs.html

Miro

Friday September 15, 2000, 9:00 AM ET

Tobacco Antagonist Zeroes in on Ritalin

By Edward Tobin

NEW YORK (Reuters) - Richard Scruggs, the lawyer who
led the settlement
between U.S. states and the tobacco industry in
1998, called the lawsuits
against the makers of hyperactivity disorder drug
Ritalin the country's ``next
class-action battleground.''

The Mississippi attorney heads up a group of
plaintiffs' lawyers alleging in two lawsuits that the makers of the drug
had conspired with psychiatrists to ``create'' the
disease known as Attention Deficit Hyperactivity Disorder (ADHD).

Scruggs, who got his first taste of national class
action suits with a successful run at the asbestos industry before
tackling big tobacco, contends that the health of
more than 4 million children is at stake because they are taking a
drug that they do not need.

The two cases, filed in state court in Hackensack,
N.J. and in San Diego federal court, name Swiss health care
group Novartis AG (NOVZn.S), the American
Psychiatric Association (APA) and nonprofit support group called
Children and Adults with
Attention-Deficit/Hyperactivity Disorder (CHADD).

The suits seek class action status and billions of
dollars in damages. The allegations are denied by both the
company and the APA.

``The main complaint is that they (the defendants)
have inappropriately expanded the definition of ADHD to include
'normal' children so that they can promote and sell
more drugs and treat more people,'' Scruggs told Reuters in a
phone interview Thursday.

``These suits represent the latest class-action
battleground in the U.S., but since it involves kids, this is that much
more important. Ninety percent of all Ritalin is
sold in the United States. We think it's a pretty tough case to say
that ADHD is a disease that doesn't exist in Europe,
but exits here,'' he said.

Government officials, pharmaceutical companies and
medical professionals have debated over the prescribing of
Ritalin for Attention Deficit Hyperactivity Disorder
(ADHD) in children for some time. The drug has been on the
market for over 40 years, but it came under intense
pressure when the White House launched an initiative in the
spring to cut down on the number of children using
the treatment, known by the chemical name methylyphenidate.

A Novartis spokesman in Zurich said he could not
respond directly to the U.S. suits because he had not yet seen
them. But he dismissed the allegation that Novartis
conspired with the American Psychiatric Association to invent
the disorder.

``We don't think there is any merit in such class
actions,'' he said, referring to a similar suit filed in Texas in May.
``We cannot see that we have any wrongdoing in this
field.''

Regina Moran, a Novartis spokeswoman at the U.S.
pharmaceutical division in East Hanover, N.J., said the
company still had not been served with papers
pertaining to the suits as of late Thursday evening. She did point out,
however, that Ritalin has been on the generic market
for many years.

``Eighty percent of the market is generic right now,
so it is a mature product for us,'' she said.

An official for the Washington D.C.-based American
Psychiatric Association also cited similarities to the Texas suit,
and had not seen the suit. But she said as in the
Texas suit, the APA will ``defend itself vigorously'' by presenting a
mountain of scientific evidence to refute these
meritless allegations, and we are confident that we will prevail.

Scruggs, who tallied up $400 million in legal fees
from the settlement with the tobacco industry, said public health
was the main motivator in the Ritalin case, and the
ultimate goal of the lawsuit is to change the way the drug is
prescribed.

``Right now, virtually every child would fit the
diagnostic criteria today for Ritalin. They are exploiting the fears of
parents for the welfare of children to gain
inappropriately, and I think that is very reprehensible and it can have
a
widespread affect on the health of American kids,''
he said.

The lawyers are seeking certification of a
nationwide class, Scruggs said, and expect others will follow suit on
basis
that ``the criteria for disease are artificially
broad so that they can include more kids and sell more drugs.''

But one industry expert was skeptical that such a
suit would get very far.

``My sense is that the symptoms of ADHD are pretty
well defined and there are a number of clinical criteria required
before a child is allowed to go on the drug,''
Merrill Lynch analyst James Culverwell said from London.

``When the child does take the drug, it is generally
remarkably effective. So any suggestion that this disease is
make-believe seems highly unlikely,'' he said.
[end]

--
http://www.angelfire.com/nj/odszkodowania

Sent via Deja.com http://www.deja.com/
Before you buy.